Sabina Chiaretti | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study	CANCERS	2023
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front‐line with paediatric‐inspired regimens: A retrospective multicentre Campus ALL study	BRITISH JOURNAL OF HAEMATOLOGY	2023
Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study	BRITISH JOURNAL OF HAEMATOLOGY	2023
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational campus acute lymphoblastic leukemia study	HAEMATOLOGICA	2022
Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia	LEUKEMIA & LYMPHOMA	2022
Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial	AMERICAN JOURNAL OF HEMATOLOGY	2022
Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia	THE JOURNAL OF MOLECULAR DIAGNOSTICS	2022
Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biases	HEMATOLOGICAL ONCOLOGY	2022
Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail populations	VACCINE. X	2022
Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2022
ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings	LEUKEMIA & LYMPHOMA	2022
Digital Droplet PCR for Minimal Residual Disease Assessment in Philadelphia-Positive Acute Lymphoblastic Leukemia Using IG/TR Genes and BCR/ABL1 as Markers. Preliminary Results of a Comparative Analysis	BloodBLOOD	2022
COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report	HAEMATOLOGICA	2022
Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group	LEUKEMIA RESEARCH	2022
Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia	THE JOURNAL OF MOLECULAR DIAGNOSTICS	2022
Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia	THE NEW ENGLAND JOURNAL OF MEDICINE	2022
Modern Management Options for Ph+ ALL	CANCERS	2022
Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia	FRONTIERS IN ONCOLOGY	2022
A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients. Final results of the GIMEMA LAL1509 protocol	HAEMATOLOGICA	2021
MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia	GENES, CHROMOSOMES & CANCER	2021

Progetti di Ricerca

Dissecting and redefining the interplay between minimal residual disease and genetic features of Ph-like ALL:
The BCR/ABL1-like acute lymphoblastic leukemia (ALL) predictor: refinement of clinical and biological features of BCR/ABL1-like ALL patients, and validation and reproducibility of the diagnostic method